{"prompt": "['Alliance A171601', 'HEPATOBILIARY DISORDERS - Hepatic failure; Hepatobiliary disorders - Other (bile duct obstruction);', 'Hepatobiliary disorders- - Other (jaundice)', 'IMMUNE SYSTEM DISORDERS - Allergic reaction', 'INJURY, POISONING AND PROCEDURAL COMPLICATIONS - Fall; Fracture', 'INVESTIGATIONS - Alkaline phosphatase increased; Bloodbilirubin increased; CPK increased; Creatinine', 'increased; Ejection fraction decreased; GGT increased; INR increased Weightloss', 'METABOLISM AND NUTRITION DISORDERS - Dehydration; Hypercalcemia; Hyperglycemia;', 'Hyperkalemia; Hypermagnesemia; Hyperuricemia; Hypoalbuminemia; Hypocalcemia; Hypokalemia;', 'Hyponatremia; Hypophosphatemia; Metabolismand nutrition dis sorders - Other (failure to thrive)', 'MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS - Arthralgia; Backpain; Flankpain;', 'Generalized muscle weakness; Muscle cramp; Musculoskeletal and connective tissuedisorder -Other -', '(osteomyelitis); Myalgia; Neckpain; Osteonecrosis; Pain in extremity', 'NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL. CYSTS AND POLYPS) - Treatment', 'related secondary malignancy', 'NERVOUS SYSTEM DISORDERS - Dizziness; Dysesthesia; Dysphasia; Intracranial hemorrhage; Nervous', 'systemdisorders - Other (peripheralneuropathy) Syncope', 'PSYCHIATRIC DISORDERS - Confusion; Insomnia; Psychiatric disorders - Other (altered mental status)', 'RENAL AND URINARY DISORDERS - Acute kidney injury; Hematuria', 'RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS - Cough; Dyspnea; Hypoxia;', 'Oropharyngealpain; Pleuraleffusion; Postnasal drip; Pulmonary edema; Pulmonary hypertension', 'SKIN AND SUBCUTANEOUS TISSUE DISORDERS - Hyperhidrosis; Pruritus', 'VASCULAR DISORDERS - Hypertension; Hypotension', 'Note: Palbociclib (PD-0332991) in combination with other agents could cause an exacerbation of any adverse event', 'currently knownto be caused by the other agent, or the combinationma result in events never previously', 'associated with either agent.', '44', 'NCIVersion Date: 5/29/2020', 'Update 5']['Alliance A171601', '10.0', 'DRUG INFORMATION', '10.1 General Considerations:', 'All study agents are to be administered at the registering institution.', '10.2 Palbociclib', 'IND Exempt: Palbociclib is IND exempt as used in this trial. This exemption has been', 'determined by attestation that neither the investigator nor sponsor intends to seek a new', 'indication for use or to support any other signific ant change in the labeling or product advertising', 'for Palbociclib; this investigation will use an approved route of administration and dosage of', 'Palbociclib and has no factors that increase the risk of the product; this investigation will be in', 'compliance with 21CFR parts 56, 50, and 312.7; and neither the investigator nor sponsor will', 'promote or represent that Palbociclib is safe or effective for the context that is under', 'investigation in this study.', 'Procurement', 'Palbociclib is a commercially available agent and filled with prescription.', 'Formulation', 'Palbociclib is supplied as a 125 mg, 100 mg, or 75 mg tablet. Palbociclib is a yellow to orange', 'powder and the 125mg capsule is an opaque hard gelatin, size 0 capsules with a caramel cap and', 'body, printed with white ink \"Pfizer\" on the cap, and \"PBC 125\" on the body. The 100 mg', 'capsules are opaque hard gelatin capsules, size 1, with caramel cap and light orange body,', 'printed with white ink \"Pfizer\" on the cap and \"PBC 100\" on the body. The 75 mg capsules are', 'opaque hard gelatin capsules, size 2, with light orange cap and body, printed with white ink', '\"Pfizer\" on the cap and \"PBC 75\" on the body.', 'Inactive ingredients present in the capsule include: Microcrystalline cellulose, lactose', 'monohydrate, sodium starch glycolate, colloidal silicon dioxide, magnesium stearate, and hard', 'gelatin capsule shells', 'The light orange, light orange/caramel and caramel opaque capsule shells contain gelatin, red', 'iron oxide, yellow iron oxide, and titanium dioxide; and the printing ink contains shellac,', 'titanium dioxide, ammonium hydroxide, propylene glycol and simethicone', 'Storage and Stability', 'The intact bottles should be stored at 20\u00b0Cto 25\u00b0C (68\u00b0F to 77\u00b0F); excursions permitted between', '15 to 30\u00b0C (59 to 86\u00b0F)', 'Administration', 'Dose: 125mg of palbocic lib administered orally once a day around the same time every day for', '21 consecutive days followed by 7 days off to comprise a cycle of 28 days.', 'Route of Administration: Orally with meals and patients should be encouraged to take their dose', 'at approximately the same time each day. If a patient vomits or misses a dose, an additional dose', 'should not be taken that day. Instead the next prescribed dose should be taken at the usual time.', 'Palbociclib capsules should be swallowed whole (do not chew, crush, or open them prior to', 'swallowing). No capsule should be ingested if it is broken, cracked, or otherwise not intact.', 'Patients should avoid consumption of grapefruit or grapefruit juice.', '45', 'NCIVersion Date: 5/29/2020', 'Update 5']\n\n###\n\n", "completion": "END"}